Anavex Proceeding with Phase 2 Trial to Assess Anavex 2-73 for Rett Syndrome
After the U.S. Food and Drug Administration recently approved an investigational new drug application for Anavex 2-73, Anavex Life Sciences is proceeding with its Phase 2 clinical trial of the medication in Rett syndrome patients, the company announced. The trial (NCT03758924) will assess the safety, tolerability,…